-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NzM/1MeIF873DfKS++LRH1OhjznYwrEQPutt43iAcq+oq/L6TFlRY70iDmsx/w2C
 l5rn3/oldHlrwmc2IjjCTw==

<SEC-DOCUMENT>0000950144-07-000298.txt : 20070315
<SEC-HEADER>0000950144-07-000298.hdr.sgml : 20070315
<ACCEPTANCE-DATETIME>20070116155251
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950144-07-000298
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20070116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHODONTIX INC
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			21000
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			21000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>SEC Response Letter</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morrison &#038; Foerster LLP<BR>
1290 Avenue of the Americas<BR>
New York, NY 10104<BR>
Telephone: 212-468-8000<BR>
Facsimile: 212-468-7900<BR>
www.mofo.com

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">January&nbsp;16, 2007
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Writer&#146;s Direct Contact
</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">212.468.8163</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">JTanenbaum@mofo.com
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Ad&#233; K. Heyliger<BR>
Ms.&nbsp;Elaine Wolfe<BR>
Ms.&nbsp;Pam Carmody<BR>
Attorney-Advisors<BR>
Division of Corporate Finance<BR>
United States Securities and Exchange Commission<BR>
100 F. Street, N.E., Mail Stop 7010<BR>
Washington, D.C. 20549

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">RE:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Orthodontix, Inc.<BR>
Schedule&nbsp;14F-1 filed on December&nbsp;18, 2006<BR>
File No.&nbsp;005-50118</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On behalf of our client, Orthodontix, Inc., a Florida corporation (the &#147;<U>Company</U>&#148;),
transmitted herewith are responses to the Staff&#146;s comments to the Information Statement filed on
Schedule&nbsp;14F-1 by the Company (the &#147;<U>Schedule&nbsp;14F-1</U>&#148;), which comments were set forth in the
Staff&#146;s letter dated January&nbsp;12, 2007 (the &#147;<U>Comment Letter</U>&#148;) to Joshua Goldstein of
Morrison &#038; Foerster LLP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For ease of reference, we have noted the Staff&#146;s comments in bold faced type and the responses
in regular type. Per our discussions with the Staff, no amendments to the Schedule&nbsp;14F-1 are being
made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>The Merger, Page 2</U>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>We note your response to prior comment 1. Please provide your analysis as to
why you believe Orthodontix should not be considered a party to the merger,
particularly in light of the fact that Orthodontix is a party to the Merger Agreement
and Plan of Reorganization (Exhibit&nbsp;10.10 to the Form&nbsp;8-</B>
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Page 2
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>K filed January&nbsp;8, 2007) and the fact that Orthodontix is also providing the merger
consideration in the form of Orthodontix common stock.</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The transaction completed pursuant to the Merger Agreement and Plan of
Reorganization (&#147;<U>Agreement</U>&#148;) made and entered as of August&nbsp;21, 2006, by and
among the Company, Protalix Acquisition Co., Ltd., an Israeli company
(&#147;<U>Acquisition Subsidiary</U>&#148;), which was a wholly-owned subsidiary of the
Company, and Protalix Ltd., an Israeli company (&#147;<U>Protalix</U>&#148;) was completed in
the form of a reverse triangular merger. In the reverse triangular merger, Protalix
and Acquisition Subsidiary were the parties to the merger itself, not the Company.
Protalix merged with and into Acquisition Subsidiary and is the surviving company,
and, accordingly, Protalix became a wholly-owned subsidiary of the Company. By
completing the transaction in the form of a reverse triangular merger, the Company
was not subject to the shareholder consent requirements under the Florida Business
Corporation Act, or FBCA, which would have been required if the transaction was
effected by way of a direct forward merger. As set forth in our previous letter,
Section&nbsp;607.1101 of the FBCA requires approval only from those
shareholders who hold shares in a company that is subject to the merger.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At the time of the merger, Protalix and Acquisition Subsidiary were both Israeli
companies and, accordingly, the merger was subject to the Israeli Companies Law.
The merger was approved by the shareholders of Protalix and by the sole shareholder
of Acquisition Subsidiary, which in this case was the Company. In addition, the
merger was approved by the board of directors of each of the Company, Acquisition
Subsidiary and Protalix. The merger complied with the Israeli Companies Law.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The fact that the Company was a party to the Agreement does not necessitate that the
Company is a party to the merger itself. Rather, the Company was a party to the
Agreement to help facilitate the transaction. The Company made the representations,
warranties, covenants, and indemnities that are customary in merger agreements and
required by the counterparties to the transaction. In addition, the fact that the
Company provided the consideration to Protalix&#146;s shareholders in connection with the
transaction is a feature of a reverse triangular merger and does not make the
Company a party to the merger.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please note that the Company has authorized us to inform you that it acknowledges that the
Company is responsible for the adequacy and accuracy of the disclosure in the filing; that Staff
comments or changes to disclosure in response to staff comments do not foreclose the Commission
from taking any action with respect to the filing; and that the Company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please call the undersigned at the telephone number set forth above or Joseph Magnas at (212)
336-4170 with any questions or comments you may have regarding the responses set forth herein. In
addition, please send all written correspondence directly to the undersigned and Joseph
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Page 3
</DIV>


<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Magnas of Morrison &#038; Foerster LLP, 1290 Avenue of the Americas, New York, New York 10104,
telecopy (212)&nbsp;468-7900, with copies to David Aviezer, Ph.D., the Company&#146;s Chief Executive Officer
at 2 Snunit Street, Science Park, P.O.B. 455, Carmiel 20100, Israel, telecopy &#043;972-4-988-9489.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Sincerely,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">/s/ James R. Tanenbaum
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">cc: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>David Aviezer, Ph.D.<BR>
Yossi Maimon</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
